The new year will bring excitement and new opportunities for the Terasaki Institute for Biomedical Innovation (TIBI). The long-awaited final construction of TIBI’s new 50,000 square foot facility in Woodland Hills is due for completion near the end of 2022, and employees will be moving in during the month of January 2023.
(LOS ANGELES) – A collaborative team, which includes scientists from the Terasaki Institute for Biomedical Innovation (TIBI), University of Illinois Chicago (UIC), and Pohang University of Science and Technology (POSTECH) has elucidated some key points on how the generation of cartilage in the joints is facilitated and how alternative bone formation can be avoided. Their findings could pave the way for designing more strategically engineered transplants for a less costly, more effective means of treating cartilage damage in the joints than current methods.
November 21, 2022
(LOS ANGELES) – A collaborative team of scientists from the Terasaki Institute for Biomedical Innovation and the University of Nebraska Medical Center has developed a fibrous aerogel that promotes faster and more effective healing of diabetic wounds. As detailed in their publication in Advanced Functional Materials, the micro/macrochannels engineered within the aerogel facilitate the ability to heal chronic diabetic wounds, while a novel protein incorporated into the aerogel provides anti-microbial capabilities and promotes wound tissue coverage and new blood vessel formation.
(LOS ANGELES) – Aneurysms, abnormal enlargement or ballooning in the wall of blood vessels can result in rupture and fatal bleeding. To treat aneurysms, it is essential to stop the blood flow to the affected area and prevent rupture of the vessel. Existing treatments for treating aneurysms include catheter-delivered stainless-steel coils or injectable biomaterials placed at the aneurysm site; however coils sometimes migrate, necessitating repeat procedures. Furthermore, there are problems with injectable biomaterials currently on the market, such as high cost, leakage, cytotoxic effects, and catheter clogs.
November 11, 2022
(LOS ANGELES) – The Terasaki Institute for Biomedical Innovation (TIBI) will be hosting the Terasaki Innovation Summit on March 8-10, 2023, at the UCLA Meyer & Renee Luskin Center in Los Angeles. This inaugural event will focus on improving technological and entrepreneurial translation of personalized medicines – bringing biomedical innovations from the laboratory to the real world.
By Ramadan Assi
In its tenth anniversary year, the annual WISH 2022 summit focused on four core themes: Sports and Health, Disability, Wellbeing, and the COVID-19 Legacy. The 2022 summit was unique, as it took place a few weeks before one of the most internationally anticipated sport events, the 2022 FIFA World Cup, which is scheduled to take place in Doha, Qatar, from November 20, 2022, to December 18, 2022.
September 20, 2022
(LOS ANGELES) - These critical medical conditions are often treated using catheter-delivered blocking agents. The blocking agents are delivered into the vessels to stop blood flow in the affected area until the vessel wall can heal. The blocking material can then be removed or allowed to degrade naturally.
.png)
By Megan Bettilyon
Not all science leads to innovative outcomes – in fact, it’s rare when the day-to-day work of a wet-lab comes across something new. You can, however, stack the deck in your favor by encouraging yourself, and your team, to try something new. Push the boundaries of what is known and be willing to accept failure as a step toward success. You can choose to be innovative; you can choose to surround yourself with people who think differently. This is when the magic happens. This is where Terasaki recently found a way to change the game in how we can bring novel therapeutics to market faster, cheaper, and more effectively.